MedTrace Logo

Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder

NCT06655129 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-10-23

No results posted yet for this study

Summary

The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders:

* Excessive Hairiness (Hirsutism, Hypertrichosis...)
* Vascular lesions (Rosacea….)
* Pigmented lesions (Lentigo et melasma)
* Acne vulgaris

Conditions

  • Excessive Hairiness
  • Vascular Lesion
  • Pigmented Lesions
  • Acne Vulgaris

Interventions

DEVICE

intense pulsed light

intense pulsed light (IPL) using the Medical Device Anthelia

Sponsors & Collaborators

  • Eurofeedback

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-20
Primary Completion
2024-12-30
Completion
2025-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06655129 on ClinicalTrials.gov